G
Greenland Mines Ltd.
Biotechnology: Biological Products (No Diagnostic Substances) company
Key Metrics of Greenland Mines Ltd.
Revenue—FY 2023
Operating income−$631K▲ 3.9% YoY
Net profit−$707K▼ 157.4% YoY
Shareholders' equity−$443K
Market cap$57.2MGRML · $4.18
Competitors10identified
About Greenland Mines Ltd.
Sectors
Company details
- Founded
- 2022
- Listed
- Nasdaq: GRML (since 2022)
Operational Areas of Greenland Mines Ltd.
Pharmaceuticals & Healthcare›Biotechnology & Vaccines
Company summary
Legal nameGreenland Mines Ltd.
TickerGRML
ExchangeNasdaq
CountryUnited States
SEC CIK0001907223
Listed since2022
IndustryBiotechnology: Biological Products (No Diagnostic Substances)
SectorPharmaceuticals & Healthcare · Biotechnology & Vaccines
Website—
US market & SEC filings
GRML · Nasdaq · SEC CIK 0001907223
Last price · 04 Nov 2026
$4.18
+4.76%
Market cap$57.2M
P/E—On FY 2023 diluted EPS
Volume782,368
SectorHealth CareBiotechnology: Biological Products (No Diagnostic Substances)
Country · IPOUnited StatesListed 2022
GRML share price
Premium
Annual results (SEC EDGAR)
Revenue, operating income, net income, EPS, cash flow, assets, liabilities, equity and debt for every year filed with the SEC are part of the premium plan.
Sign in to continue See plans & pricingVendor checks & payment capacity
Sign in with access to company financials to review vendor evidence.
Registered office and contact
Registered office—
GSTIN—
Email—
Website—
Members / shareholders—
Directors and key people
Directors are read from the MGT-7 annual return and AOC-4 signatories.
Competitors of Greenland Mines Ltd.
Competitors10identified
Countries1most in United States
Top competitors by location
| Company | Description | Domain | Founded | Location |
|---|---|---|---|---|
| Part of Vertex Pharmaceuticals. | vrtx.com | 1991 | United States | |
| Biotechnology & Vaccines · Pharmaceuticals & Healthcare | modernatx.com | 2018 | United States | |
 Becton Dickinson |
Biotechnology & Vaccines · Pharmaceuticals & Healthcare | bd.com | — | United States |
| Part of Illumina. | illumina.com | 2000 | United States | |
| Biotechnology & Vaccines · Pharmaceuticals & Healthcare | guardanthealth.com | 2018 | United States | |
| Biotechnology & Vaccines · Pharmaceuticals & Healthcare | revvity.com | — | United States | |
| Biotechnology & Vaccines · Pharmaceuticals & Healthcare | exelixis.com | 2000 | United States | |
| Biotechnology & Vaccines · Pharmaceuticals & Healthcare | neurocrine.com | 1996 | United States | |
| Biotechnology & Vaccines · Pharmaceuticals & Healthcare | biomarin.com | 1999 | United States | |
| Biotechnology & Vaccines · Pharmaceuticals & Healthcare | bio-rad.com | 1980 | United States |
Charges (secured borrowings)
0 registered charges. Lenders, amounts and dates are part of the premium plan.
Statutory auditors
Auditors are read from the AOC-4 auditor's report section.
Business activities and related parties
Principal business activities and related-party transactions are read from MGT-7 and AOC-4 filings.
Filings
No filings on record yet.